



Letter to the Editor

When to evaluate the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes?



Haohui He, Tao Zhou*

Department of Cardiology, The Third Affiliated Hospital of Southern Medical University, Guangdong, China

ARTICLE INFO

Article history:

Received 15 September 2018

Accepted 21 September 2018

Keywords:

ACEF score

Acute coronary syndrome

Dear editor,

Recently, one interesting article reported the relationship between the age, creatinine, and ejection fraction (ACEF) score and the all-cause mortality of the patients with acute coronary syndromes (ACS) [1]. In this study, 1901 patients were enrolled, and further divided into low-risk (ACEF ≤ 1.45), intermediate-risk (ACEF > 1.45 and ≤ 2.0) and high-risk (ACEF > 2.0) groups according to the ACEF score (age/left ventricular ejection fraction + 1 [if creatinine $> 176 \mu\text{mol/L}$]). One-year mortality of ACS patients in low-risk, intermediate-risk, and high-risk groups were 1.6%, 5.6%, and 23.0%, respectively. Furthermore, the ACEF score was also related with an increased risk of major adverse cardiac and cerebrovascular events (adjusted HR 2.23, $p < 0.001$), and transient ischemic attack/stroke (adjusted HR 2.58, $p < 0.001$).

Obviously, aging and decreasing left ventricular ejection fraction related to increasing mortality within ACS patients [2]. Serum creatinine, as a marker of kidney function, may reflect to renal disease, and the

relationship between renal disease and ACS has been well verified [3]. However, it seemed confused in the timing of evaluating the ACEF score of ACS patients, before or after the coronary angiography? Ischemic mitral regurgitation (IMR) arised in 13% to 50% patients of acute myocardial infarction [4], which may result in overestimating the left ventricular ejection fraction. With the improving of ischemic lesions, mild or even moderate IMR may disappear after percutaneous coronary intervention (PCI) treatment. As a result, the ACEF scores may be different of these patients before and after PCI treatment. A timely ACEF score evaluation would be more accurate in predicting prognosis of ACS patients.

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

References

- [1] B.E. Stähli, M.B. Wischnewsky, P. Jakob, et al., Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes, *Int. J. Cardiol.* 270 (2018) 7–13.
- [2] S.A. Berns, E.A. Schmidt, O.A. Naqirnyak, et al., Assessment of outcomes and treatment tactics in patients with non-ST-elevation acute coronary syndrome: data of five-year follow-up, *Kardiologija* 7 (2018) 32–40.
- [3] L. Duncan, J. Heathcote, O. Djurdjev, A. Levin, Screening for renal disease using serum creatinine: who are we missing? *Nephrol. Dial. Transplant.* 16 (2001) 1042–1045.
- [4] K. Kim, S. Kali, M. Kasamoto, R. Murai, et al., Renin-angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction, *Open Heart* 4 (2017), e000637.

* Corresponding author.

E-mail address: hjh_qwe123456@163.com (T. Zhou).